British anti-Lewisite (dimercaprol): An amazing history

Annals of Emergency Medicine

Volumn 41, Issue 3, 2003, Pages 378-383

  Vilensky, Joel A ^a   Redman, Kent ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; BISMUTH; COPPER; DIMERCAPROL; GOLD; LEWISITE; NICKEL;

ABDOMINAL PAIN; ABSCESS; ARSENIC POISONING; BLEPHAROSPASM; BURNING SENSATION; CHEMICAL WARFARE; CONJUNCTIVITIS; DRUG CHOICE; DRUG METABOLISM; EMERGENCY TREATMENT; FEVER; HEADACHE; HEAVY METAL POISONING; HUMAN; HYPERTENSION; INJECTION SITE; LACRIMATION; MERCURIALISM; NAUSEA; PRIORITY JOURNAL; REVIEW; RHINORRHEA; SALIVATION DISORDER; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; VOMITING; WILSON DISEASE;

EID: 0037373105     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1067/mem.2003.72     Document Type: Review

References (39)

1. Poisindex System (database). Greenwood, CO: Micromedex; 2002.
2. Klassen CD. Heavy metals and heavy metal antagonists. In: Hardman J, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2002:1851-1875.
3. Rudolph AM, Kamei RK, Overby KJ, eds. Rudolph's Fundamentals of Pediatrics. New York, NY: McGraw-Hill; 2002.
4. Denny-Brown D, Porter H. The effect of BAL (2,3-Dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease). N Engl J Med. 1951;245:917-925.
5. Chemical Corps Association. The Chemical Warfare Service in World War II. New York, NY: Reinhold Publishing; 1948.
6. Larson E. British anti-Lewisite, BAL. Confinia Neurologica. 1950;10:108-126.
7. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2002;49(RR-4):1-14.
8. Goldman M, Dacre JC. Lewisite: its chemistry, toxicology and biological effects. Rev Environ Contam Toxicol. 1989;110:75-115.
9. Compton JAF. Military Chemical and Biological Agents. Caldwell, NJ: The Telford Press; 1987.
10. Nieuwland JA. Some Reactions of Acetylene. Notre Dame, IN: Notre Dame Press; 1904.
11. Waitt AH. Gas Warfare. New York, NY: Duell, Sloan and Pearce; 1941.
12. Ord MA, Stocken LA. A contribution of chemical defence in World War II. Trends Biochem Sci. 2000;25:253-256.
13. Peters RA, Stocken LA, Thompson RHS. British anti-Lewisite (BAL). Nature. 1945;156:616-619.
14. Waters LL, Stock C. BAL (British anti-Lewisite). Science. 1945;102:601-606.
15. Munro NB, Talmadge SS, Griffin GD, et al. The sources, fate and toxicity of chemical warfare agent degradation Environ Health Perspect. 1999;107:933-974.
16. Stocken LA, Thompson RHS. Reactions of British anti-Lewisite with arsenic and other metals in living systems. Physiol Rev. 1949;29:168-192.
17. Peters RA, Sinclair HM, Thompson RHS. An analysis of the inhibition of pyruvate oxidase by arsenicals in relation to the enzyme theory of vesication. Biochem J. 1946;40:516-524.
18. Reed LJ, DeBusk BG, Gunsalus IC, et al. Crystalline alpha-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase. Science. 1951;114:93-94.
19. Reed LJ. A trail of research from lipoic acid to α-keto acid dehydrogenase complexes. J Biol Chem. 2001;276:38329-38336.
20. Webb EC, Van Heyningen R. The action of British anti-Lewisite (BAL) on enzyme systems. Biochem J. 1947;41:74-78.
21. Eagle H, Magnuson HJ. The systematic treatment of 227 cases of arsenic poisoning (encephalitis, dermatitis, blood dyscrasias, jaundice, fever) with 2,3-dimercaptopropanol (BAL). Am J Syph Gonorrhea Venereal Dis. 1946;30:420-441.
22. Longcope WT, Luetscher JA Jr. Clinical use of 2,3-dimercaptopropanol. XI. The treatment of acute mercury poisoning by BAL. J Clin Invest. 1946;25:557-567.
23. Cohen A, Goldman J, Dubbs AW. The treatment of acute gold and arsenic poisoning. JAMA. 1947;133:749-752.
24. Ragan C, Boots RH. The treatment of gold dermatitis. JAMA. 1947;133:752-754.
25. MacLeod JG. BAL in the treatment of gold toxicity. Ann Rheum Dis. 1948;7:143-151.
26. Margolis HM, Caplan PS. BAL in the treatment of toxicity from gold. Ann Intern Med. 1947;27:353-360.
27. Deichmann WB, Gerade HW. Symptomatology and Therapy of Toxicological Emergencies. New York, NY: Academic; 1964.
28. Sulzberger MB, Baer RL, Kanof A. Clinical uses of 2,3-dimercaptopropanol (BAL). III. Studies on the toxicity of BAL on percutaneous and parenteral administration. J Clin Invest. 1946;25:474-479.
29. Menkes JH. Disorders of metal metabolism. In: Rowland LP, ed. Merritt's Neurology. 10th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2000:543-548.
30. Cumings JN. The copper and iron content of brain and liver in the normal and in hepatolenticular degeneration. Brain. 1948;71:410-415.
31. Mandelbrote BM, Stanier MW, Thompson RHS, et al. Studies on copper metabolism in demyelinating diseases of the central nervous system. Brain. 1948;71:212-228.
32. Porter H. Amino acid excretion in degenerative diseases of the nervous system. J Lab Clin Med. 1949;34:1623-1626.
33. Denny-Brown D, Porter H. The effect of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease). Proc Am Neurol Assoc. 1951:79-84.
34. Science News Letter. December 29, 1951.
35. Walshe JM. Penicillamine. A new oral therapy for Wilson's disease. Am J Med. 1956;21:487-495.
36. Brewer GJ. The treatment of Wilson's disease. Adv Exp Med Biol. 1999;448:115-126.
37. Scheinberg IH, Sternlieb I. Wilson's Disease. Philadelphia, PA: Saunders; 1984.
38. Scheinberg IH, Sternlieb I. Treatment of the neurologic manifestations of Wilson's disease. Arch Neurol. 1995;52:339-340.
39. Yoneti L. Surviving Wilson's disease. Clin Med. 2001;1:72-74.